NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
STALEVO 200 (carbidopa, levodopa, and entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 2003.
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 200 is a fixed-dose oral tablet combining carbidopa, levodopa, and entacapone for Parkinson's disease management. It works by inhibiting catechol O-methyltransferase (COMT) to extend levodopa availability and reduce motor fluctuations in patients experiencing wearing-off phenomena. The aromatic amino acid formulation addresses mid-dose motor complications in advanced Parkinson's disease.
$0.151MPart D
LOE ApproachingDeclining
Legacy product in declining phase with minimal claims volume; limited team expansion expected and focus shifting to defense and managed care contracting.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on STALEVO 200 positions professionals in a mature, declining-revenue franchise with emphasis on defensive commercial strategy rather than growth. Career advancement depends on driving reimbursement negotiations, generic transition planning, and managed-care contracting in a consolidating Parkinson's disease market.
Brand Manager
Worked on STALEVO 200 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.